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OBJECTIVES This individually randomized, open-label, parallel-group pilot study was designed to test the
hypothesis that the ability of loop diuretics to interfere with cardiac fibrosis in chronic heart
failure (CHF) may be different between compounds.
BACKGROUND The apparent mortality and cardiac benefits seen in studies comparing torasemide with
furosemide in CHF suggest that torasemide may have beneficial effects beyond diuresis (e.g.,
on the process of cardiac fibrosis).
METHODS Patients with New York Heart Association functional class II to IV CHF received diuretic
therapy with either 10 to 20 mg/day oral torasemide (n  19) or 20 to 40 mg/day oral
furosemide (n  17), in addition to their existing standard CHF therapy for eight months.
At baseline and after eight months, right septal endomyocardial biopsies were obtained to
quantify collagen volume fraction (CVF) with an automated image analysis system. Serum
carboxy-terminal peptide of procollagen type I (PIP) and serum carboxy-terminal telopeptide
of collagen type I (CITP), indexes of collagen type I synthesis and degradation, respectively,
were measured by specific radioimmunoassays.
RESULTS In torasemide-treated patients, CVF decreased from 7.96  0.54% to 4.48  0.26% (p 
0.01), and PIP decreased from 143  7 to 111  3 g/l (p  0.01). Neither CVF nor PIP
changed significantly in furosemide-treated patients. In all patients, CVF was directly
correlated with PIP (r  0.88, p  0.001) before and after treatment. No changes in CITP
were observed with treatment in either group.
CONCLUSIONS These findings suggest that loop diuretics possess different abilities to reverse myocardial
fibrosis and reduce collagen type I synthesis in patients with CHF. (J Am Coll Cardiol
2004;43:2028–35) © 2004 by the American College of Cardiology Foundationc
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roop diuretics, such as furosemide and torasemide, are
urrently recommended for the treatment of chronic heart
ailure (CHF) (1,2). In a recent report of the prospective
ORasemide In Chronic heart failure (TORIC) study
nvolving 1,377 CHF patients, the use of torasemide was
ssociated with a lower mortality than furosemide (3).
urthermore, it has been reported recently that torasemide
mproves left ventricular (LV) diastolic function in CHF
atients to a greater extent than furosemide, despite the fact
hat torasemide induces a more pronounced stimulation of
he renin-angiotensin-aldosterone system (4). Because both
iuretics exert similar renal effects (5,6), it is likely that
orasemide has beneficial effects other than diuresis in
atients with CHF.
Numerous findings, as reviewed elsewhere (7), emphasize
he role of myocardial accumulation of collagen fibers in the
eterioration of LV function in CHF. It has been proposed
hat myocardial fibrosis is the result of both increased
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cs, Guipuzcoa Policlinics, Donostia University Hospital, San Sebastia´n, Spain.
rantxa Gonza´lez received a research training grant (00/9296) from the Fondo de
nvestigaciones Sanitarias (FIS), Ministry of Health, Spain. This study was partly
upported by an unrestricted grant from Roche Pharmaceuticals.
Manuscript received November 6, 2003; revised manuscript received December 18,
m003, accepted December 23, 2003.ollagen synthesis by fibroblasts and unchanged or de-
reased extracellular fibrillar collagen degradation (8). It has
een proposed that hemodynamic and nonhemodynamic
actors may be responsible for such an imbalance (9). For
nstance, a number of findings suggest that aldosterone may
lay a role in myocardial fibrosis (10,11). Furthermore,
ecent clinical studies have shown that the addition of the
ldosterone antagonist spironolactone to the regimens of
atients with heart failure is associated with changes in
erum markers of fibrillar collagen turnover, suggesting a
ecreased formation of these molecules (12,13). Interest-
ngly, it has been shown that torasemide, but not furo-
emide, interferes with the secretion and receptor-ligand
inding of aldosterone (4,14,15). We have therefore hy-
othesized that torasemide may interfere with mechanisms
nvolved in alterations of fibrillar collagen turnover and
yocardial fibrosis in patients with CHF. To test this
ypothesis, the present study was designed to compare
hanges in the fraction of myocardial volume occupied by
ollagen, or collagen volume fraction (CVF), and the serum
oncentrations of the carboxy-terminal peptide of procolla-
en type I (PIP) and the carboxy-terminal telopeptide of
ollagen type I (CITP), indexes of collagen type I synthesis
nd degradation, respectively (16,17), in CHF patients
eceiving either torasemide or furosemide as diuretic treat-
ent. The primary end point was the change in CVF of
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June 2, 2004:2028–35 Loop Diuretics and Myocardial Fibrosisndomyocardial biopsies from baseline to eight months, and
he secondary end point was the change in serum concen-
rations of PIP and CITP.
ETHODS
atients and study protocol. This was an individually
andomized, open-label, parallel-group pilot study. All sub-
ects gave written, informed consent before participating in
he study. The investigation conformed to the principles
utlined in the Helsinki Declaration. All patients were seen
t the General Hospital (San Sebastia´n), and the biopsies
ere obtained at the Guipuzcoa Polyclinic (San Sebastia´n).
oth centers are integrated in the Donostia University
ospital, and the study protocol was approved by the
nstitutional Review Committee of the Donostia University
ospital.
The study population consisted of 39 Caucasian patients
ith different cardiomyopathies. The diagnosis of heart
ailure syndrome was made on a clinical basis, by the
resence of at least one major and two minor criteria of the
ramingham Study (1). In addition, the heart failure diag-
osis was reinforced by the presence of a depressed ejection
raction (EF) and/or Doppler signs of diastolic dysfunction
n all patients. Furthermore, hemodynamic evidence of
yocardial failure was obtained in each patient by measur-
ng elevated LV end-diastolic pressure and pulmonary
apillary wedge pressure (12 mm Hg in both cases). After
stablishing the diagnosis of heart failure, the patient’s
linical status was assessed according to his or her extent of
isability, according to the New York Heart Association
NYHA) functional classification (18).
All patients initially selected had a previous diagnosis of
YHA functional class II to IV heart failure in accordance
ith the aforementioned criteria. In addition, they had been
eceiving standard heart failure treatment (loop diuretic plus
n angiotensin-converting enzyme [ACE] inhibitor or an-
iotensin type I receptor antagonist plus beta blocker) for
he previous six months when enrolled. Thus, they were
onsidered as patients having CHF. Patients definitively
nrolled were those who did not present with exclusion
riteria (previous acute myocardial infarction, significant
alvular disease, diabetes mellitus, treatment with spirono-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CHF  chronic heart failure
CITP  carboxy-terminal telopeptide of collagen type I
CVF  collagen volume fraction
DT  deceleration time
EF  ejection fraction
KLV  left ventricular chamber stiffness
LVMI  left ventricular mass index
NYHA  New York Heart Association
PIP  carboxy-terminal peptide of procollagen type Iactone for at least one year before enrollment, significant Plectrolyte disturbances, severe ventricular arrhythmia, com-
lete atrioventricular block and dyspnea due to lung disease,
nd conditions associated with alterations in serum levels of
IP, such as alcoholic liver disease, metabolic bone disease,
nd hyperthyroidism).
No washout phase was performed to ensure continuous
eart failure treatment. Patients were randomly assigned to
eceive either torasemide or furosemide. After randomiza-
ion, 20 patients were assigned to 10 to 20 mg/day to-
asemide (torasemide group) and 19 patients to 20 to 40
g/day furosemide (furosemide group) for eight months.
hese doses have been shown to be comparable in terms of
iuretic effect (19). Existing salt intake restriction (4 g/day)
nd concomitant CHF medication were continued during
he study, with the exception of aldosterone antagonists,
hich were not permitted during the study. We chose a
reatment period of eight months, just long enough to allow
he removal of a significant amount of collagen from the
yocardium, in keeping with the half-life of fibrillar colla-
en (20).
At baseline and after eight months of treatment, a
umber of procedures were performed to assess different
arameters.
ssessment of pressures. Systolic and diastolic blood pres-
ures were monitored in a sitting position at each visit by use
f standard cuff equipment. Type I and V phases of the
orotkoff sounds were used; three measurements were
btained in each patient, at 5-min intervals, and averaged.
Left ventricular end-diastolic pressure and pulmonary
apillary wedge pressure were measured with a microma-
ometer catheter system during the angiographic examina-
ion, before the biopsy was taken.
ssessment of LV mass and function. Two-dimensional
chocardiograms, targeted M-mode recordings, and Dopp-
er ultrasound measurements were obtained in each patient.
eft ventricular mass was measured, and the left ventricular
ass index (LVMI) was calculated, as previously described
21). The following pulsed Doppler measurements were
btained: maximum early transmitral velocity in diastole
VE); maximum late transmitral velocity in diastole (VA);
he deceleration time of the early mitral filling wave (DT);
nd isovolumic relaxation time. Left ventricular chamber
tiffness (KLV) was calculated according to the following
ormula (22,23): KLV  (0.07/DT)
2, where DT was calcu-
ated as the time from the peak of the E wave to the
ero-velocity intercept of the regression line of the E-wave
elocity deceleration profile (24). Ejection fraction was
alculated from the measurements performed in a
echnetium-99m ventriculography (multigated acquisition
can) (25). Diastolic heart failure was defined as an EF
0.50, as well as alterations in the VE/VA ratio, isovolumic
elaxation time, and/or DT (26). Systolic heart failure was
efined as an EF 0.50.
iochemical determinations. Serum potassium and serum
reatinine were determined by standard laboratory methods.
lasma aldosterone was measured by radioimmunoassay
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Loop Diuretics and Myocardial Fibrosis June 2, 2004:2028–35sing a commercial kit. Serum PIP was determined by
adioimmunoassay, according to a method previously de-
cribed (27). The inter- and intra-assay variations for
etermining PIP were 7% and 3%, respectively. The sensi-
ivity (lower detection limit) was 1.20 g/l of PIP. Serum
ITP was determined by radioimmunoassay, according to a
ethod previously described (28). The inter- and intra-
ssay variations for determining CITP were both8%. The
ensitivity (lower detection limit) was 0.50 g/l of CITP.
istomorphologic study. Transvenous endomyocardial
iopsies were taken from the middle area of the interven-
ricular septum with a Cordis 96-cm (7F) bioptome, under
uoroscopic guidance after angiographic examination, as
reviously reported (21). Up to three biopsies were taken in
ach intervention. The rationale for the use of this proce-
ure is based on the previous finding that patchy fibrosis
resent in the septum in postmortem tissue from human
earts is representative of fibrosis existing in the free wall
29). The biopsy procedure was well tolerated in all cases.
istologic evaluation was performed as previously reported
21). Collagen volume fraction was determined by quanti-
ative morphometry with an automated image analysis
ystem (AnalySYS, Soft Imaging System GmbH, Hammer,
ermany) in sections stained with collagen-specific picro-
irius red (sirius red F3BA in aqueous picric acid). The
istomorphologic study was performed by a pathologist
linded to the other characteristics of the patients under
tudy.
tatistical analysis. Differences in parameters at baseline
nd after treatment between CHF patients treated with
ither torasemide or furosemide were tested by the Student
test for unpaired data once normality was demonstrated
Shapiro-Wilks test); otherwise, a nonparametric test
Mann-Whitney U test) was used. Differences in parame-
ers before and after treatment within each group of patients
ere tested by the Student t test for paired data once
ormality was demonstrated (Shapiro-Wilks test); other-
ise, a nonparametric test (Wilcoxon test) was used. Cat-
gorical variables were analyzed by the chi-square Fisher
xact test when necessary. The correlation between contin-
ously distributed variables was tested by univariate regres-
ion analysis. Data are expressed as the mean value SEM.
value of p  0.05 was considered statistically significant.
ESULTS
atient compliance and baseline characteristics. At the
nd of the treatment period, patients in the torasemide
roup (n  19) and the furosemide group (n  17) received
ean daily dosages of 10.6  0.6 mg and 32.2  3.2 mg,
espectively. Baseline medications other than loop diuretics
ere maintained unchanged during the treatment period in
he two groups of patients. No adverse effects or complica-
ions occurred during the study in either group.
During the treatment period, we observed a small drop-
ut rate of patients at their own request; one patient in the morasemide group and two patients in the furosemide group
ithdrew consent.
Baseline clinical characteristics were compared for pa-
ients who completed the study (Table 1). No significant
ifferences in clinical parameters were observed between the
roups in the parameters tested. Although baseline values of
VF, PIP, and CITP were similar in the two groups of
atients, they were well above the control values for these
arameters reported by our group in healthy subjects
21,27,28,30).
The CVF tended to be higher in patients with diastolic
HF than in patients with systolic CHF in the two groups
furosemide group: 7.76  1.34% vs. 6.97  1.08%;
orasemide group: 8.32  0.55% vs. 7.47  1.01%), but the
ifferences did not reach statistical significance.
ffects of treatment. Although CVF decreased in the
orasemide group (7.96  0.54% vs. 4.48  0.26%, p 
.01), it remained unchanged in the furosemide group (7.29
0.98% vs. 6.47  0.74%, p  NS) (Fig. 1). In addition,
VF after treatment was lower (p  0.005) in the to-
asemide group than in the furosemide group. Figure 2
llustrates treatment-induced changes in myocardial fibrosis
n one representative patient from each group.
The effect of torasemide on CVF was more intense in
atients with diastolic CHF (final value of 4.37  0.21%, p
0.001) than in patients with systolic CHF (final value of
.81 0.53%, p 0.05). The effects of furosemide on CVF
ere similar in patients with diastolic CHF (final value of
.66  1.16%, p  NS) than in patients with systolic CHF
final value of 6.10  0.82%, p  NS).
Administration of torasemide was associated with a
eduction in the serum concentration of PIP (143  7 g/l
s. 111  3 g/l, p  0.01) (Fig. 3). In contrast, serum PIP
id not change after treatment in the furosemide group (133
12 g/l vs. 133  7 g/l, p  NS) (Fig. 3). Serum PIP
easured after treatment was lower (p  0.01) in the
orasemide group than in the furosemide group. A direct
orrelation was found between serum PIP and CVF (y 
8.08  9.41x, r  0.880, p  0.001) in all CHF patients
efore and after treatment (Fig. 4).
As shown in Figure 5, serum CITP remained unchanged
fter treatment in the torasemide group (5.16  0.84 g/l
s. 5.14  0.70 g/l) and the furosemide group (4.89 
.92 g/l vs. 5.26  0.81 g/l). No correlation was found
etween serum CITP and CVF.
As reported in Table 1, the number of patients showing
mprovement of at least one grade in NYHA functional
lass was greater (p  0.05) in the torasemide group than in
he furosemide group. The KLV values showed a nonsignif-
cant trend toward a decrease in torasemide- but not
urosemide-treated patients. The EF values showed a non-
ignificant trend toward an increase in torasemide- but not
urosemide-treated patients. Plasma levels of aldosterone
emained unchanged with treatment in the two groups of
HF patients. Changes induced by treatment in the re-
aining parameters tested were similar in torasemide- and
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alues of these parameters were similar in the two groups of
atients.
ISCUSSION
ffects on myocardial fibrosis. The main finding of this
tudy is that long-term administration of either torasemide
r furosemide is associated with different effects on myocar-
ial fibrosis in CHF patients.
Fibrosis probably plays an important role in diastolic
ysfunction and systolic pump function (9), and it is one of
he structural substrates for fatal arrhythmogenicity (31),
Table 1. Effects of Treatment on Parameters A
Finished the Study
Parameter
Furosemide
At Baseline A
Age (yrs) 63  3
Gender (M/F) 13/4
Body weight (kg) 76  3
Causes of CHF
HHD 10
IHD 4
IDCM 2
Alcoholism 1
Types of CHF
Diastolic 8
Systolic 9
Medications
ACEIs or ARAs 17
Beta-blockers 17
Digoxin 5
Diuretics
Furosemide 10
Torasemide 1
Spironolactone 0
Thiazide  amiloride 4
Blood pressure
Systolic (mm Hg) 140  4
Diastolic (mm Hg) 88  2
Hemodynamic parameters
LVEDP (mm Hg) 19  2
PCWP (mm Hg) 16  2
Cardiac parameters
LVMI (g/m2) 166  20
KLV (mm Hg/ml) 0.14  0.02
EF (%) 38  4
NYHA functional class*
I —
II 5
III 11
IV 1
Blood parameters
Potassium (mmol/l) 4.52  0.10
Creatinine (mg/dl) 1.08  0.05
Aldosteronel (pg/ml) 125  25
*p 0.01 for changes in NYHA class after treatment †p 0.01
or number of patients.
ACEIs angiotensin-converting enzyme inhibitors; ARAs
 ejection fraction; HHD hypertensive heart disease; IDCM
KLV  left ventricular chamber stiffness; LVEDP  left ven
NYHA  New York Heart Association; PCWP  pulmonarhus playing a major role in the progression of heart failurend sudden death. We (30,32) and others (33,34) have
hown that a reduction of myocardial fibrosis is associated
ith improvement of LV function parameters in hyperten-
ive patients receiving long-term treatment with different
ntihypertensive agents. Our findings that torasemide exerts
n antifibrotic effect in CHF patients, whereas furosemide
oes not, may be related to the greater improvement of
YHA functional class observed in torasemide-treated
HF patients than in those treated with furosemide. This is
upported by changes in parameters assessing cardiac func-
ion (e.g., KLV and EF). Although these were not statisti-
ally significant, overall changes are consistent with the
onclusion that torasemide, but not furosemide, exerts
sed in Chronic Heart Failure Patients Who
up Torasemide Group
reatment At Baseline After Treatment
63  3
15/4
 3 84  3 82  3
11
5
1
2
10
9
17 19 19
17 19 19
5 6 6
17 6 0
0 6 19
0 0 0
4 0 0
 4† 147  3 126  2†
 2† 92  2 74  2†
17  1
15  1
 15 148  11 142  11
 0.02 0.17  0.02 0.14  0.02
 4 40  4 44  3
0 — 0
11 8 16
5 9 3
1 2 0
 0.12 4.66  0.11 4.51  0.13
 0.09 1.11  0.06 1.19  0.05
 13 132  30 113  19
values at baseline. Data are expressed as the mean value SEM
iotensin receptor antagonists; CHF chronic heart failure; EF
pathic dilated cardiomyopathy; IHD ischemic heart disease;
end-diastolic pressure; LVMI  left ventricular mass index;
ary wedge pressure.sses
Gro
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Loop Diuretics and Myocardial Fibrosis June 2, 2004:2028–35eneficial effects on myocardial function in the hearts of
HF patients. This can be of particular interest in diastolic
HF, as suggested by our observation that the ability of
orasemide to reduce myocardial fibrosis tended to be higher
n patients with diastolic CHF than in those with systolic
HF. It is clear that further studies enrolling larger samples
f patients are required to test this possibility.
igure 1. Effects of furosemide (n  17) and torasemide (n  19) on
ollagen volume fraction (CVF) in patients with chronic heart failure. NS
nonsignificant.
igure 2. Histologic sections of a myocardial biopsy specimen from a pati
anel) treatment with furosemide. Histologic sections of a myocardial biops
reatment with torasemide. (Picrosirius red stain; magnification 20.) CVF Although a similar reduction in blood pressure was
ttained in the two groups of CHF patients after treatment,
nly torasemide-treated patients exhibited a significant
eduction in myocardial fibrosis. Therefore, the possibility
xists that the ability of torasemide to decrease myocardial
brosis in CHF patients is not only linked to diminished
echanical overload but may also be related to interference
ith chronic heart failure before (upper left panel) and after (upper right
imen from a patient before (lower left panel) and after (lower right panel)
igure 3. Effects of furosemide (n  17) and torasemide (n19) on serum
arboxy-terminal peptide of procollagen type I (PIP) in patients with
hronic heart failure. NS  nonsignificant.ent w
y speccollagen volume fraction.
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June 2, 2004:2028–35 Loop Diuretics and Myocardial Fibrosisith humoral profibrotic factors such as aldosterone (10,11)
nd angiotensin II (35). Although recent experimental (14)
nd clinical (4) findings show that torasemide, but not
urosemide, inhibits the secretion of aldosterone, data
erein reported do not support the ability of torasemide to
iminish plasma levels of this hormone. Nevertheless, the
ossibility remains that, as shown in in vitro studies,
orasemide blocks the binding of the hormone to its
ineralocorticoid receptor (15). On the other hand, it has
een reported that, in vitro, torasemide, but not furosemide,
nhibits angiotensin II-stimulated signaling pathways in
ascular cells, whereas furosemide does not (36,37). Alter-
atively, torasemide may stimulate antifibrotic humoral
actors such as prostacyclin (38,39). In fact, it has been
eported that in patients with CHF, torasemide stimulates
he release of prostacyclin to a greater extent than does
urosemide (40). Clearly, further studies are required to
nvestigate the precise mechanism(s) of the antifibrotic
ffect of torasemide in CHF patients.
ffects on collagen type I turnover. A second finding of
his study is that the synthesis of collagen type I molecules,
s assessed by the serum level of PIP, is reduced after
igure 4. Direct correlation (y  68.08  9.41x) between collagen volume
raction (CVF) and serum carboxy-terminal peptide of procollagen type I
PIP) in patients with chronic heart failure before and after treatment.
igure 5. Effects of furosemide (n  17) and torasemide (n  19) on
erum carboxy-terminal telopeptide of collage type I (CITP) in patientsmith chronic heart failure. NS  nonsignificant.reatment in torasemide-treated CHF patients, but not in
urosemide-treated CHF patients.
The 100-kd C-peptide PIP is freed during the extracel-
ular processing of procollagen type I into the fibril-forming
ollagen type I molecules (41). The released peptide is
ound in an immunochemically intact form in blood. A
ertain amount of clinical and experimental evidence sup-
orts the notion that the serum concentration of PIP reflects
he rate of extracellular synthesis of collagen type I (9,42).
ue to its pharmacologic properties (5,43), torasemide does
ot seem to be able to interfere with the hepatobiliary
limination of PIP. Thus, our finding that serum PIP
iminishes in torasemide-treated CHF patients suggests
hat this agent inhibits the extracellular synthesis of collagen
ype I molecules.
A number of observations have led to the proposal that
he increased production of PIP is associated with exagger-
ted myocardial deposition of collagen type I fibers in
ardiac diseases (44–46). This is further reinforced by the
orrelation found here between CVF and PIP in all CHF
atients before and after treatment. It is thus tempting to
peculate that the ability of torasemide to inhibit the cardiac
ynthesis of collagen type I might be involved in its capacity
o reduce myocardial fibrosis in CHF patients.
The 12-kd, cross-linked C-terminal telopeptide CITP,
hich results from the cleavage of collagen type I by
ollagenase, is found in an immunochemically intact form in
lood (47). On the basis of a number of clinical and
xperimental observations, it has been suggested that the
erum concentration of CITP reflects the rate of extracel-
ular degradation of collagen type I (17,42). Because circu-
ating CITP is excreted by glomerular filtration, it is
nlikely that torasemide modifies the serum concentration
f this peptide through changes in its rate of renal clearance.
hus, the tendency toward increased CITP, despite the
ecrease in PIP, observed in torasemide-treated CHF pa-
ients suggests that this compound stimulates the degrada-
ion of collagen type I fibers and tends to restore the
quilibrium between collagen type I synthesis and degrada-
ion in CHF patients.
tudy limitations. This was an individually randomized,
pen-label, parallel-group pilot study involving a relatively
mall number of patients. However, because of the nature of
he hypothesis under investigation, this design is appropri-
te. While appreciating that therapy with ACE inhibitors or
ngiotensin receptor antagonists and beta-blockers may
ave influenced the main parameters tested, one must
onsider that, as standard therapies for CHF, it would be
nreasonable to withdraw any of them for the purposes of
his investigation, and in this study, the groups were
alanced for these therapies at baseline.
As picrosirius red binds to collagen molecules other than
ype I, such as type III, and an excess of collagen type III
eposition occurs in the myocardium of patients with CHF
8), we cannot exclude the possibility that the changes in
yocardial fibrosis found in our patients are also caused by
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olecules.
onclusions. We have shown, for the first time, that
ong-term treatment with different loop diuretics may have
variable impact on myocardial fibrosis in CHF patients. In
act, although torasemide-treated patients exhibited a re-
uction of myocardial collagen accumulation and a diminu-
ion of collagen type I synthesis, furosemide-treated patients
id not. Further studies are required to definitively prove
hat torasemide possesses cardioreparative properties that, in
urn, may provide an additional benefit, on top of ACE
nhibitors or angiotensin receptor antagonists and beta-
lockers, in CHF patients receiving this agent.
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